Incyte (MEX:INCY) Accounts Payable: MXN4,123 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:INCY Incyte Corp MEX:INCY
83 GF Score
Price MXN2,067.00
GF Value MXN1,817.72
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Accounts Payable?

Incyte MEX:INCY 83 Accounts Payable is MXN4,123 Mil as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 83/100 and a GF Value™ of MXN1,817.72 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Incyte's Accounts Payable for the quarter that ended in Mar. 2026 was MXN4,123 Mil.

Incyte's quarterly Accounts Payable increased from Sep. 2025 (MXN3,154 Mil) to Dec. 2025 (MXN3,780 Mil) and increased from Dec. 2025 (MXN3,780 Mil) to Mar. 2026 (MXN4,123 Mil).

Incyte's annual Accounts Payable increased from Dec. 2023 (MXN1,860 Mil) to Dec. 2024 (MXN4,118 Mil) but then declined from Dec. 2024 (MXN4,118 Mil) to Dec. 2025 (MXN3,780 Mil).

Incyte Accounts Payable Historical Data

* Premium members only.

The historical data trend for Incyte's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Accounts Payable Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,530.67 5,411.04 1,860.40 4,118.27 3,780.08

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4,000.34 4,539.61 3,153.83 3,780.08 4,122.71
MEX:INCY
83GF Score
Incyte Corp MEX:INCY
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of MXN4,123 Mil mean?
Incyte (MEX:INCY) has a Accounts Payable of MXN4,123 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Incyte and its competitors.
Is Incyte's Accounts Payable too high?
Incyte's current Accounts Payable is MXN4,123 Mil. Overall, Incyte has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Accounts Payable compare to INSM and BNTX?
Incyte's Accounts Payable of MXN4,123 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Incyte and its competitors. Incyte's current Accounts Payable is MXN4,123 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,817.72, compared to a current price of MXN2,067.00 — trading 13.7% above its estimated fair value. The current Accounts Payable is MXN4,123 Mil. Incyte's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Accounts Payable is MXN4,123 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,067.00 is trading 13.7% above its estimated GF Value™ of MXN1,817.72. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Accounts Payable: MXN4,123 Mil
  • GF Value™: MXN1,817.72 vs. price of MXN2,067.00 (13.7% above fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
83GF Score

Get the complete analysis for MEX:INCY

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,067.00
Price
MXN1,817.72
GF Value